are an important target of estrogen action through both the classical genomic (i.e. nuclear-initiated) activities of estrogen receptors ␣ and ␤ (ER␣ and ER␤) and the rapid "nongenomic" (i.e. membrane-initiated) activation of ER that stimulates intracellular phosphorylation pathways. We tested the hypothesis that the red wine polyphenol trans-resveratrol activates MAPK signaling via rapid ER activation in bovine aortic EC, human umbilical vein EC, and human microvascular EC. We report that bovine aortic EC, human umbilical vein EC, and human microvascular EC express ER␣ and ER␤. We demonstrate that resveratrol and estradiol (E 2 ) rapidly activated MAPK in a MEK-1, Src, matrix metalloproteinase, and epidermal growth factor receptor-dependent manner. Importantly, resveratrol activated MAPK and endothelial nitric-oxide synthase (eNOS) at nM concentrations (i.e. an order of magnitude less than that required for ER genomic activity) and concentrations possibly achieved transiently in serum following oral red wine consumption. Co-treatment with ER antagonists ICI 182,780 or 4-hydroxytamoxifen blocked resveratrol-or E 2 -induced MAPK and eNOS activation, indicating ER dependence. We demonstrate for the first time that ER␣-and ER␤-selective agonists propylpyrazole triol and diarylpropionitrile, respectively, stimulate MAPK and eNOS activity. A red but not a white wine extract also activated MAPK, and activity was directly correlated with the resveratrol concentration. These data suggest that ER may play a role in the rapid effects of resveratrol in EC and that some of the atheroprotective effects of resveratrol may be mediated through rapid activation of ER signaling in EC.
been attributed to the polyphenol fraction of red wine (1) . A key polyphenol in red wine is resveratrol, trans-3,5,4Ј-trihydroxystilbene, from grape skin. Red wine contains 1-75 mg of transresveratrol/liter (3) . Studies in male rats demonstrated that an alcohol-free red wine extract and resveratrol protect the heart from ischemia reperfusion injury (4) . Rodent studies showed that orally administered resveratrol is absorbed in the gut, has high affinity for heart and liver (5, 6) , and is metabolized to glucuronides that have a t1 ⁄2 of ϳ1.5 h (7). A recurrent question is whether resveratrol, at concentrations present in red wine, is effective in vivo. The oral absorption of 25 mg of trans-resvertrol/70 kg subject in white wine, grape juice, and vegetable juice was studied in healthy men (8) . Peak serum resveratrol was 40 nM at ϳ30 min after consumption (8) . High concentrations of resveratrol (i.e. 10 -100 M) induced endothelial nitricoxide synthase (eNOS) gene expression in cultured endothelial cells (EC), suggesting that resveratrol may provide cardioprotection by increasing nitric oxide (NO) levels (9 -11) . Additionally, resveratrol acutely increased NO production in human umbilical vein endothelial cells (HUVEC) after a 2-min exposure (11) . However, the mechanism for this acute activation is unknown.
Resveratrol binds and increases the transcriptional activity of estrogen receptors ␣ and ␤ (ER␣ and ER␤) at 50 -100 M (12, 13) . Estrogens were long thought to have beneficial effects on cardiovascular parameters. However, the Women's Health Initiative prospective hormone replacement therapy trial was recently terminated because of increased CHD risk (relative risk ϭ 1.29) in the hormone replacement therapy group (14) and pulmonary embolism in both the hormone replacement therapy (14) and estrogen replacement therapy groups; these findings raise questions regarding the role of estrogens in cardiovascular function and disease. It is noteworthy that estrogen replacement therapy did not alter CHD risk and that some clinicians believe hormone replacement therapy can be effective in the prevention of CHD (15) . ER␣ gene polymorphisms are postulated to play a role in CHD and may be part of the reason for the Women's Health Initiative trial results (16) . Further, numerous animal studies consistently demonstrate that E 2 inhibits the progression of atherosclerosis (reviewed in Ref. 17) .
The vasculature is an important target of estrogen action through both the classical genomic pathways involving regulation of gene transcription by ER␣ and ER␤ as well as rapid, non-genomic activation of intracellular signaling pathways (reviewed in Ref. 18) . The rapid vasodilating effect of E 2 is related to its ability to increase NO by stimulating eNOS expression and activity (reviewed in Ref. 19) . A subpopulation of ER␣ is associated with caveolae in the endothelial plasma membrane (reviewed in Ref. 20) . Membrane ER␣ is coupled via a G␣ i protein to MAPK and eNOS in EC (21) and to Src, MMP-9, MMP-2, EGF-R, and MAPK in breast cancer cells and BAEC (22) . Membrane ER␣ activates ERK, c-Jun NH 2 -terminal kinase, and p38 mitogen-activated protein kinases (23) . Understanding how ER␣, which has nuclear localization sequences (24) and is, whether liganded or not, predominantly nuclear (25) , localizes to the cell membrane was recently elucidated. Transfection studies in Chinese hamster ovary cells demonstrated that serine 522 in the ligand binding domain of ER␣ interacts with Caveolin-1 (23) . Caveolin-1 is a structural protein in caveolae that binds Src, Grb7, Raf, Ras, MEK, EGF-R, and ER␣ at the plasma membrane forming a "signalsome" for rapid activation of intracellular signaling (22) . The goal of the present study was to determine whether resveratrol has rapid effects on MAPK and eNOS activities in EC and to determine whether common intermediates in the MAPK signaling pathway were involved in resveratrol and E 2 action.
EXPERIMENTAL PROCEDURES
Cell Treatments-BAEC were provided by Dr. Yang Wang at passage 2 (26) or purchased from Cambrex (Walkersville, MD). HUVEC were purchased from Cambrex. Human microvascular endothelial cells (HMEC) were provided by Dr. J. Steven Alexander of the Louisiana State University. BAEC were used between passage 3 and 8 and maintained in RPMI 1640 (Invitrogen) supplemented with 15% heat-inactivated fetal bovine serum (Hyclone, Logan, UT) and 1% penicillin-streptomycin (Invitrogen). HMEC was maintained in MCDB 131 (Sigma) supplemented with 10% heat-inactivated fetal bovine serum, 10 ng/ml EGF (Sigma), 1 mg/ml hydrocortisone (Sigma), and 1% penicillin-streptomycin (Invitrogen). HUVEC were used between passage 2 and 8 maintained in EGM-2 (Cambrex) supplemented with 2% fetal bovine serum. EC were serum-starved for 24 h prior to each experiment and treated in medium without serum plus the indicated chemical for 20 min. Whole cell extracts (WCE) were prepared in radioimmune precipitation assay buffer (27) . Protein concentration was determined by a Bio-Rad protein assay.
Chemicals-trans-Resveratrol was generously provided by Pharma Science (Montreal, Canada). R,R-5,11-cis-Diethyl-5,6,11,12-tetrahydrochrysene-2,8-diol (R,R-THC) was generously provided by Dr. John A. Katzenellenbogen (28) . GV (white) and LM (red) wine extracts were kindly provided by Dr. Alois Jungbauer (29) . The following treatments were purchased: E 2 (Sigma); 4-hydroxytamoxifen (Research Biomedicals International); ICI 182,780, 4,4Ј,4Љ-(4-propyl-c-pyrazole-1,3,5-triyl)-tris-phenol (PPT), and 2,3-bis(4-hydroxyphenyl)-propionitrile (DPN) from Tocris (Ellisville, MO). TAPI-1 was from Peptides International (Louisville, KY). Tyrphostin AG1478 and PP2 were from Calbiochem.
Transient Transfection-HMEC were transiently transfected with pcDNA3 (Invitrogen), pUSE-Src-K297R, kinase inactive (Upstate Biotechnology, Lake Placid, NY), p3XFLAG-CMV7-ERK2 (wild-type rat ERK2), or p3XFLAG-CMV7-ERK2-K52R dominant negative (DN) generously provided by Dr. Melanie Cobb (30) using FuGENE 6 (Roche Applied Science). HUVEC were transfected with small interfering RNA (siRNA) to MEK1 (siGENOME SMARTpool TM reagent, catalogue number M-003571-00, Dharmacon, Lafayette, CO) using Nucleofection (Amaxa). HUVEC were treated with EtOH or resveratrol 48 h after transfection as indicated in the Fig. 5 legend.
Western Blot Analysis-WCE (40 g of protein) were separated on 10% SDS polyacrylamide gels, electroblotted onto polyvinylidene difluoride membranes (31) , and probed as indicated in the figure legends. Antibodies for MAPK(ERK1/2) and phospho-p44/42 MAPK(P-ERK1/2) were from Cell Signaling Technology (Beverly, MA). ER␣ AER320 and ER␤ H150 antibodies were from Neomarkers (Fremont, CA) and Santa Cruz Biotechnologies (Santa Cruz, CA), respectively. Baculovirus-expressed rhER␣ was prepared from Sf21 cells as described (32) . Baculovirus-expressed rhER␤ (catalogue number P2718, i.e. hER␤1 (long form, 530 kDa)) was purchased from Panvera (Madison, WI). Phospho-ER␣ (Ser-118) antibody was from Cell Signaling. Glyceraldehyde-3-phosphate dehydrogenase and ␤-actin antibodies were from RDI (Flanders, NJ) and Sigma, respectively. Immunodetection employed Super Signal West Pico chemiluminescent substrate (Pierce) on Kodak BioMaxML film (Eastman Kodak Co.) (33) . The resulting films were scanned into Adobe Photoshop version 7.0 using a Microtek ScanMaker III scanner. Un-Scan-It (Silk Scientific, Orem, UT) was used to quantitate the integrated optical densities (IOD) for each band. Immunoblots were first probed for P-MAPK and then stripped and reprobed for MAPK. IOD were added; ERK-1 plus ERK-2 equaled MAPK and P- ERK1 plus P-ERK2 equaled P-MAPK. The treatment-specific P-MAPK IOD were divided by concordant MAPK IOD in the same blot and normalized to EtOH or Me 2 SO (vehicle control), which was set to 1. Anti-Src and anti-FLAG antibodies were from Upstate Biotechnology and Sigma, respectively. Anti-phospho-Src (Tyr-416) and anti-MEK1 antibodies were from Cell Signaling.
Immunoassay-HUVEC were preincubated with 10 g/ml mouse IgG, ER␣ antibody Ab10 (Neomarkers), or ER␤ antibody H150 for 2 h prior to 15 min treatment with EtOH, E 2 or resveratrol. P-ERK and total ERK were measured in WCE by TiterZyme enzyme immunoassay from Assay Designs, Inc. (Ann Arbor, MI) according to the manufacturer's protocol.
eNOS Assay-eNOS activity was measured by the conversion of [ Statistical Analysis-Statistical analyses were performed using Student's two-tailed t test or one-way analysis of variance followed by Dunn's multiple comparison test with GraphPad prism.
RESULTS
Resveratrol and E 2 Stimulate MAPK Activation-E 2 rapidly activates one or more G proteins via membrane ER␣, resulting in activation of Src, which in turn increases the activity of MMP-2 and MMP-9, resulting in stimulation of heparin-binding (HB)-EGF secretion and activation of EGF-R, MEK-1, and MAPK in MCF-7 and ZR-75-1 breast cancer cells and in BAEC (22) . We hypothesized that resveratrol would act by this same pathway in EC. Short term resveratrol, like E 2 , stimulated MEK-1 in BAEC in a concentration-dependent manner as evidenced by phosphorylation of ERK1/2 ( Fig. 1) . Repeated experiments and statistical evaluation are summarized in Fig. 2 . It is noteworthy that activation of MAPK required only nM concentrations of resveratrol, which is 1,000 -10,000-fold lower than the concentrations of resveratrol needed for other cellular responses, e.g. transcription activity of ER␣ or ER␤ (13), antioxidant activity (34) , and inhibition of cell proliferation (reviewed in Refs. 35 and 36) . ER antagonists ICI 182,780 and 4-hydroxytamoxifen inhibited MAPK activation by resveratrol and E 2 , indicating that resveratrol-and E 2 -induced MAPK activation is mediated by binding ER (Figs. 1, C and D, and 2) . The kinetics of MAPK activation are important in cellular differentiation (37) . As shown in Fig. 3 , resveratrol and E 2 activated MAPK in BAEC, HUVEC, and HMEC in a time-dependent manner with a peak between 5 and 20 min. Activation of MAPK returned to control levels by 30 -45 min. Thus, rapid activation of MAPK by resveratrol and E 2 is similar in three different endothelial cell sources. Resveratrol gave a more robust activation of MAPK in HMEC than E 2 between 5 and 15 min and returned to control levels by 60 min. 50 values for resveratrol and E 2 for P-MAPK/MAPK activation in BAEC were 1.33 ϫ 10 Ϫ8 and 1.56 ϫ 10 Ϫ10 M, respectively. These values are significantly less than the EC 50 of 25 M resveratrol for ER␣ and ER␤ transcriptional activation of an estrogen response element reporter gene in transiently transfected MCF-7 cells (29) . A red wine extract was shown previously to have higher ER transcriptional activity than a white wine extract, results correlating with the resveratrol content of 3.06 and 0.17 mg/liter in the red and white wine extracts, respectively (29) . A 20-min treatment of BAEC with the red wine extract induced MAPK activation, whereas the white wine extract had no MAPK activity (Fig. 4A) . The red wine extract-induced MAPK activity was inhibited by ICI 182,780, indicating that the effect was ER-mediated.
Resveratrol and E 2 Activation of MAPK Is ER-, MEK-1-, MMP-, and EGF-R-dependent-The EC
The MEK1 inhibitor PD98059 blocked resveratrol and E 2 -induced MAPK phosphorylation (Fig. 4, B and C) . Activation of Src is one of the initial steps in membrane-initiated ER-mediated cell signaling (38) . PP2, a selective Src kinase inhibitor at nM concentrations, inhibited E 2 -and resveratrol-induced MAPK activation in HUVEC (Fig. 5, A and B) . To confirm the effects of the pharmacologic inhibitors, we performed transfection experiments in HMEC and HUVEC using DN or siRNA approaches. HMEC and HUVEC were selected for these experiments because these cells showed responses to resveratrol and E 2 that were similar to BAEC (Fig. 3) , and they have a higher transfection efficiency (up to 40%, data not shown) than BAEC. Transient transfection of HMEC with DN point mutants of Src or ERK2 inhibited basal and resveratrol-and E 2 -induced MAPK phosphorylation (Fig. 5C) . Levels of Src and ERK overexpression were similar in all cases, indicating the effect was due to DN function of the protein (Fig. 5D ). These data confirm the results of the chemical inhibitor studies. Transient overexpression of wild-type rat ERK2 increased basal MAPK activation, and neither resveratrol nor E 2 gave a further stimulation of MAPK in these cells. Similarly, transfection of HUVEC with siRNA directed against MEK1, decreasing MEK1 protein expression a minimum of 60%, inhibited basal and resveratrolinduced MAPK activation (Fig. 5D ). These data indicate that the increase in P-MAPK/MAPK with resveratrol or E 2 treatment is mediated by activation of Src and MEK1.
Recent data demonstrated that E 2 activation of membrane ER in breast cancer cells and BAEC leads to activation of MMP-2 and MMP-9, release of HB-EBF, and activation of EGF-R, which in turn activates MAPK (22) . We hypothesized that resveratrol would act by this same pathway. TAPI-1, an MMP inhibitor, and tyrphostin AG1478, an EGF-R tyrosine kinase inhibitor, decreased both resveratrol-and E 2 -induced MAPK phosphorylation (Fig. 5, E-G) . Taken together, these data indicate that resveratrol, like E 2 (22) , activates a cascade of events, i.e. binding ER and activating MMP, EGF-R, Src, and MEK1, leading to MAPK activation.
Resveratrol and E 2 Increase ER␣ Ser-118 Phosphorylation in EC-One downstream target of activated MAPK is ER␣ (39) . MAPK phosphorylates Ser-118 in the N-terminal activation function 1 domain of ER␣ (39) . We observed that resveratrol and E 2 rapidly induced phosphorylation of Ser-118 in ER␣ in HMEC, with a peak in P-ER␣ detected between 10 and 30 min (Fig. 6, A and B) . Similar results were detected in HUVEC and BAEC (data not shown). Pretreatment of HMEC with PD98059 (data not shown) or the Src kinase inhibitor PP2 (Fig. 6C) blocked E 2 or resveratrol stimulation of ER␣ phosphorylation. Others have reported that P-ER␣ has enhanced transcriptional activity relative to non-P-ER␣ (39) .
ER␣ and ER␤ Activate MAPK-The laboratory of John Katzenellenbogen has developed ER␣-and ER␤-selective agonists and antagonists (40 -43) . PPT and DPN selectively activate ER␣ and ER␤ at nM concentrations, respectively, whereas M concentrations are needed to activate the opposite subtype (44). The ER␣-or ER␤-selective agonists PPT (40) or DPN (42) rapidly induced MAPK phosphorylation in BAEC with the EC 50 ϭ 3.16 and 9.16 nM, respectively (Fig. 7, A and B) . These concentrations are within the range selective for each ER subtype (44) . The ER antagonist ICI 182,780 and MEK inhibitor PD98059 inhibited PPT-or DPN-induced MAPK phosphorylation, indicating that the effects of PPN and DPN were mediated by ER binding and MEK activation. The ER␤-selective antagonist/ER␣ agonist R,R-THC (28) inhibited DPN-induced MAPK phosphorylation, implying that a DPN-ER␤ interaction was responsible for the increase in P-MAPK. Fig. 7C summarizes these data. Notably, R,R-THC also inhibited PPT-induced MAPK phosphorylation. Because R,R-THC and PPT are both ER␣ agonists, this result was unexpected. A possible explana-
FIG. 4. Red wine extract activates MAPK and resveratrol, and E 2 activation of MAPK is mediated by MEK1.
A, BAEC were treated for 20 min with a 1:1000 dilution of white or red wine extracts, prepared as described (29) , alone or in combination with 1 M ICI 182,780. The P-MAPK/MAPK ratio was quantitated from Western blot analyses. B, BAEC were pretreated with the MEK1 inhibitor 10 M PD98059 for 2 h prior to the addition of 10 nM E 2 or 50 nM resveratrol for 15 min. C, quantitation of the P-MAPK/MAPK ratio. Each bar is the mean Ϯ S.E. of at least four independent experiments. a, statistically different from the EtOH control, which was set to 1, p Ͻ 0.05; b, statistically different from the indicated ligand treatment alone, p Ͻ 0.05. tion for this observation is that both ER␣ and ER␤, perhaps as heterodimers, are involved in non-genomic activation of MAPK and that inhibiting one ER subtype impedes the activity of the other. Alternatively, the selectivity of these agents may be different for extranuclear (non-genomic) versus nuclear (genomic) ER activity. R,R-THC inhibited resveratrol-induced MAPK phosphorylation, implicating resveratrol-ER␤ interaction in MAPK activation. Preincubation of HUVEC with antibodies to ER␣ or ER␤ blocked E 2 -and resveratrol-induced MAPK phosphorylation, implicating both ER␣ and ER␤ in the activation of ERK by resveratrol and E 2 (Fig. 7D) .
EC Express ER␣ and ER␤-HUVEC, HMEC, BAEC, and MCF-7 (used as a positive control because this cell line expresses both ER␣ and ER␤ proteins (45) ) express the expected masses of ER␣, ER␤1, and ER␤1s proteins, i.e. 67, 60, and 53 kDa, respectively (Fig. 8) . Based on quantitation of Western blots with rhER␣ and rhER␤ as standards and normalization of the data to ␤-actin as a loading control, we estimated that HMEC, HUVEC, BAEC, and MCF-7 express an average of 3.2, 4.3, 3.4, and 2.8 pmol of ER␣ (monomer)/g of WCE and 2.5, 2.7, 2.4, and 2.3 pmol of ER␤1 (monomer)/g of WCE, respectively. Neither the values of ER␣ nor those of ER␤ expression were significantly different between the cell lines with an n ϭ 4 -8. The ER␣ values agree with the levels of ER␣ expression in rat aorta (46) . To our knowledge, this is the first estimation of the levels of ER␤ expression in EC. To demonstrate the specificity of the antibodies used in Western blotting, baculovirus-expressed recombinant human ER␣ and ER␤1 were Western blotted (Fig. 8C) . AER320 recognized only ER␣ but not ER␤, and H150 recognized only ER␤ but not ER␣. Thus, the detection of both ER␣ and ER␤ in EC is not an artifact of antibody cross-reactivity.
Resveratrol and E 2 Activate eNOS-Previous studies reported that E 2 -activated eNOS in EC was fully inhibited by concomitant treatment with tamoxifen or ICI 182,780, indicat-
FIG. 5. Inhibition of Src, ERK2, MEK1, MMP, and EGF-R kinase blocks resveratrol and E 2 activation of MAPK.
A, HUVEC were treated with EtOH, 10 nM E 2 , or 50 nM resveratrol (Resv.) for 15 min or were preincubated with the Src kinase inhibitor 10 nM PP2 for 1 h prior to treatment, as indicated. Blots were probed for P-MAPK, stripped, and reprobed for MAPK. B, quantitation of the P-MAPK/MAPK ratio as the mean Ϯ S.E. of four independent experiments. C, HMEC were transfected with pcDNA3, DN-Src (pUSE-Src-K297R), wild-type FLAG-tagged ERK2 (pFLAG-ERK2), or DN-ERK2 (pERK2-K52R) for 48 h and treated for 15 min with EtOH, E 2 , or resveratrol (as indicated). P-MAPK/MAPK was assayed by immunoassay. Immunoblot analysis showed no alteration in total Src and that cells transfected with FLAG-ERK2 expressed the expected size of FLAG fusion protein (Western blot panels below the P-MAPK/MAPK bar graphs). D, HUVEC were transfected with siRNA to MEK1 for 48 h and treated for 15 min with EtOH or 50 nM resveratrol. Western blot analysis for P-MAPK, total MAPK, and MEK1 proteins and quantitation of the P-MAPK/MAPK ratio are shown. MEK1 expression was decreased 64% in extract 2 and 87% in extract 4. E, BAEC were treated with E 2 or resveratrol Ϯ the indicated MMP inhibitor TAPI-1 for 15 min. F, BAEC were treated with E 2 , resveratrol, and ICI 182,780 in the presence or absence of 50 M tyrphostin AG1478 for 15 min. G, quantitation of the P-MAPK/MAPK ratio. a, statistically different from the EtOH control; b, statistically different from the concordant E 2 or resveratrol value without PP2 treatment, p Ͻ 0.05. (Fig. 9A) . Concomitant treatment with ICI 182,780 inhibited E 2 -and resveratrol-stimulated eNOS, indicating that the process is ER-dependent. Preincubation of BAEC with the MEK1 inhibitor PD98059 inhibited E 2 -or resveratrol-induced eNOS activity, indicating that the MAPK pathway is involved in eNOS activation.
Treatment of BAEC with the ER␣-or ER␤-selective agonists PPT (40) or DPN (42) rapidly induced eNOS activity (Fig. 9B) . ICI 182,780 inhibited PPT-and DPN-stimulated eNOS, indicating ER dependence. These data indicate that agonist-occupied ER␣ and/or ER␤ activate eNOS in BAEC.
DISCUSSION
The primary goal of this study was to determine whether resveratrol rapidly activated MAPK and eNOS via ER activation in EC. We report a number of novel observations. We demonstrated that nM concentrations of resveratrol, like E 2 , rapidly activate MAPK in an ER-, MEK-, MMP-, Src-, and EGF-R-dependent manner in BAEC. These data suggest that resveratrol and E 2 activate the same non-genomic ER pathway that was elucidated for the rapid E 2 activation of MAPK in MCF-7 and ZR-75-1 breast cancer cells and BAEC (22) . This activation pathway is diagrammed in Fig. 10 and shows the effect of antagonists and inhibitors used in this study. We are aware that resveratrol may also activate MAPK in an ERindependent manner because ICI 182,780 blocked only ϳ70% of the resveratrol-induced MAPK activity. Previously, 10 -100 M resveratrol was reported to activate eNOS (11), concentrations that are unlikely to be achieved by reasonable red wine consumption (8) . Ours is the first report demonstrating that nM concentrations of resveratrol elicit biochemical activity in EC, concentrations achieved in human serum ϳ30 min post-resveratrol ingestion (8) . Hence, we speculate that oral ingestion of beverages containing resveratrol, such as red wine or grape juice, could result in transient serum levels, leading to activation of membrane-initiated ER signaling in EC that would activate MAPK and eNOS. We suggest that differences in resveratrol purity (all-trans versus mixed cis and trans), time course of treatment, HUVEC source, or passage (11) may account for the difference in the concentrations of resveratrol required to achieve the biological activity obtained in our experiments and previous work (9, 48 -51) . Micromolar resveratrol activated MAPK in human DU145 prostate (48) and thyroid (49) cancer cell lines with a peak of P-MAPK/MAPK detected 4 -8 h post-treatment. Conversely, resveratrol inhibited MAPK activity in human SH-SY5Ycells (50) and in porcine coronary arteries with an IC 50 ϭ 37 M (51). Because resveratrol binds ER␣ and ER␤ with a K d in the M range (13, 52, 53) and the EC 50 for resveratrol activation of estrogen response element-driven reporter gene activity was 10 M (13), our data suggest that resveratrol may be more selective for membraneinitiated versus nuclear ER. The mechanism accounting for this difference is unknown. Alternatively, it is possible that the low solubility of resveratrol (13) results in an underestimation of nuclear levels and an overestimation of the resveratrol concentration required for genomic ER activity.
A second novel observation presented here is that both resveratrol and E 2 rapidly activate eNOS in an ER-and MEK1- dependent manner because the ER antagonist ICI 182,780 and an inhibitor of MEK1, i.e. PD98059, inhibited the resveratroland E 2 -induced eNOS activity. Furthermore, to our knowledge, we present the first demonstration that the ER␤-and ER␣-selective agonists DPN and PPT activate eNOS in BAEC. Thus, we speculate that resveratrol and E 2 activate eNOS via their interaction with both ER subtypes in BAEC.
Reports on the endogenous expression of ER␣ or ER␤ in EC are mixed. For example, although HUVEC reportedly expressed both ER␣ and ER␤ at the mRNA level (54) , no ER␣ or ER␤ proteins were detected (55) . Another study showed ER␣ protein expression in HUVEC and BAEC (56) . Recently, ER␤ but not ER␣ was detected in EC in endometrial tissues of humans and primates (57) . Here we report that BAEC, HUVEC, and HMEC express full-length ER␣ and ER␤ proteins. Among the possible explanations for these differences are the EC tissue source and the manner in which the cells are maintained, because passage number and cell density are inversely correlated with membrane-associated ER␣ expression (58) .
Studies in male rats have demonstrated that an alcohol-free red wine extract and resveratrol can protect the heart from the detrimental effects of ischemia reperfusion injury as seen in reduced myocardial infarction and improved post-ischemic ventricular function (4). The cardioprotective effects of red wine and resveratrol have been associated with increased high density lipoprotein cholesterol (59); however, studies have shown that high density lipoprotein cholesterol levels explain only 50% of the protective effect of alcoholic beverages (2) . The other 50% has been attributed to decreased platelet activity (2, 60) and to reduced vascular tension (61) . The rapid vasodilating effect of E 2 is at least partially related to activation of eNOS and increased NO production (62) (63) (64) . Because NO reduces vascular tension by causing vasodilation (20) , the results reported here showing that nM concentrations of resveratrol rapidly activated eNOS are congruent with a role for resveratrol mediating cardioprotective activity via endothelial relaxation.
In conclusion, the data presented here demonstrate that nM concentrations of resveratrol and E 2 rapidly activate ER in EC, resulting in MAPK and eNOS activation. The physiological implications of the present findings are that the nM concentrations of resveratrol, which are found transiently in human circulation after modest wine consumption (8) , offer a possible mechanism for observed vascular protective effects of resveratrol in vivo. The ability of selective inhibitors, DN expression constructs, and siRNA against proteins in the pathway elucidated for the rapid stimulation of intracellular signaling by E 2 via a plasma membrane ER in breast cancer cells (22) (i.e. MMP, EGF-R, Src, and MEK) to also inhibit resveratrol-mediated MAPK activation indicates that resveratrol and E 2 act via similar pathways in EC. Future studies directed toward elucidating the regulation of ER␣ and ER␤ expression, their intracellular localization, and activity in the endothelium will provide new understanding of the physiological significance of the impact of resveratrol on vascular function. FIG. 10 . Model for resveratrol and E 2 activation of MAPK in EC. ER is localized in a "signalsome complex" that includes Caveolin-1, which binds Src, Grb7, Raf, Ras, MEK, EGF-R, and ER␣ at the plasma membrane and may be coupled to G proteins (20) that activate MEK1/2 and that cause release of Ca 2ϩ from intracellular pools. This model is based primarily on studies in breast cancer cells and BAEC (22) , wherein E 2 binding to ER activates Src, which activates MMPs that cleave pro-HB-EGF to bioactivate HB-EGF, a ligand for EGF-R. Activation of EGF-R kinase in turn activates the MAPK pathway. MAPK activates eNOS, releasing NO (20) . Chemicals that inhibit the activity of steps in the pathway used in experiments are indicated. The data presented here suggest that resveratrol also activates this pathway. IP 3 , inositol 1,4,5-trisphosphate; PLC, phospholipase C; PKC, protein kinase C.
